Top

Published in:

Open Access 01-12-2018 | Research article

Predictive equation of metastasis in patients with malignant ovarian epithelial tumors with the Ca-125 marker

Authors: Juan Fernando Sánchez Vega, Magdali del Rocío Murillo Bacilio, Adrián Santiago Vintimilla Condoy, Araceli Miroslava Palta González, José Alfredo Crespo Astudillo, Franklin Geovany Mora-Bravo, MsC

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

Cancer antigen (CA) 125 (CA-125) is used in ovarian cancer detection and monitoring, whose serum level has a positive correlation with tumor stage. The aim of this study was to obtain a prediction metastasis equation in a group of patients with ovarian cancer based on Ca-125.

Methods

A 2-group comparative observational study was conducted at a single oncologic institution (SOLCA) in Cuenca-Ecuador. All patients who were diagnosed with ovarian cancer between January 1996 and December 2016 were included in the current study. Group 1 (G1) patients with the I and II International Federation of Gynecology and Obstetrics (FIGO) stage and Metastasis Group (MG), with III and IV stage, were subdivided. A logistic regression equation was performed to predict metastasis based on Logarithm of serum Ca-125 levels.

Results

We included 85 cases in G1 and 64 patients in MG, with 47.8 ± 15 years (G1) and 57.5 ± 13.6 years (MG) of age (P < 0.001). Mortality in G1 was 2 cases (3.1%) and 53 cases (62.4%) in MG (P < 0.001). The CA-125 serum level was 163.5 ± 236 in G1 and 1220.9 ± 1940 u / ml in MG (P < 0.001). The equation to predict metastasis = (Age*0.053) + [(Logarithm Ca-125 value) * 1.078] − 8.163 with an OR 2.940 (CI 95% 2.046–4.223) P < 0.001. The sensitivity of the equation was 82.4% and the specificity was 79.7%.

Conclusions

It is possible to predict the presence of metastasis in a group of patients with ovarian cancer based on Ca-125.

Available only for authorised users

Trétarre B, Molinié F, Woronoff AS, Bossard N, Bessaoud F, Marrer E, et al. Ovarian cancer in France: trends in incidence, mortality and survival, 1980-2012. Gynecol Oncol. 2015;139(2):324–9. https://doi.org/10.1016/j.ygyno.2015.09.013.CrossRefPubMed

Coussy F, Chéreau E, Daraï E, Dhombres F, Lotz JP, Rouzier R, et al. Interest of CA 125 level in management of ovarian cancer. Gynecol Obstet Fertil. 2011;39(5):296–301. https://doi.org/10.1016/j.gyobfe.2010.10.018.22.CrossRefPubMed

Paul P, Talukder S, Sangma MA, Saha PL, Begum M, Razi AZ, et al. Detection of ovarian tumor by color Doppler ultrasonography and CA-125. Mymensingh Med J. 2017;26(4):705–9. PubMed PMID: 29208855.PubMed

Morales-Vásquez F, Pedernera E, Reynaga-Obregón J, López-Basave HN, Gómora MJ, Carlón E, et al. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma. J Ovarian Res. 2016;9:41. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936203/.CrossRefPubMedPubMedCentral

Varras M. Benefits and limitations of ultrasonographic evaluation of uterine adnexal lesions in early detection of ovarian cancer. Clin Exp Obstet Gynecol. 2004;31(2):85–98. Review. PubMed PMID: 15266758.PubMed

Dolores-Velázquez R, Bustamante-Montes LP, Romero-Fierro JR, Gómez-Plata E, Ocampo-García KG, Dueñas-González A. Relación entre niveles de CA-125 y características clínicas e histopatológicas en el cáncer epitelial de ovario. Gac Mex Oncol. 2014;13(4):207–14.

Tiwari RK, Saha K, Mukhopadhyay D, Datta C, Chatterjee U, Ghosh TK. Evaluation of preoperative serum levels of CA 125 and expression of p53 in ovarian neoplasms: a prospective Clinicopathological study in a tertiary care hospital. J Obstet Gynaecol India. 2016;66(2):107–14. https://doi.org/10.1007/s13224-014-0611-7.CrossRefPubMed

Schmidt C. CA-125: a biomarker put to the test. J Natl Cancer Inst. 2011;103(17):1290–1.CrossRefPubMed

Worzfeld T, Pogge von Strandmann E, Huber M, Adhikary T, Wagner U, Reinartz S, Müller R. The unique molecular and cellular microenvironment of ovarian Cancer. Front Oncol. 2017;7:24. https://doi.org/10.3389/fonc.2017.00024.CrossRefPubMedPubMedCentral

10.

Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch. 2017;470(2):125–42. https://doi.org/10.1007/s00428-016-2040-8.CrossRefPubMed

11.

Prat J, Belhadj H, Berek J, Bermudez A, Bhatla N, Cain J, et al. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5. https://doi.org/10.1016/j.ijgo.2013.10.001.CrossRefPubMed

12.

Willis S, Villalobos VM, Gevaert O, Abramovitz M, Williams C, Sikic BI, et al. Single gene prognostic biomarkers in ovarian Cancer: a meta-analysis. PLoS One. 2016;11(2):e0149183.CrossRefPubMedPubMedCentral

13.

Prat J. FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26(2):87–9. https://doi.org/10.3802/jgo.2015.26.2.87.CrossRefPubMedPubMedCentral

14.

Zivanovic O, Sima C, Iasonos A, Bell-McGuinn K, Sabbatini P, Leitao M, et al. Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian Cancer. Gynecol Oncol. 2009;115(2):2–17. https://doi.org/10.1016/j.ygyno.2009.06.038.CrossRef

Title: Predictive equation of metastasis in patients with malignant ovarian epithelial tumors with the Ca-125 marker
Authors: Juan Fernando Sánchez Vega
Magdali del Rocío Murillo Bacilio
Adrián Santiago Vintimilla Condoy
Araceli Miroslava Palta González
José Alfredo Crespo Astudillo
Franklin Geovany Mora-Bravo, MsC
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-4499-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Aggregation of lipid rafts activates c-met and c-Src in non-small cell lung cancer cells

Targeting colorectal cancer cell metabolism through development of cisplatin and metformin nano-cubosomes

Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis

Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials

Keynote webinar | Spotlight on antibody–drug conjugates in cancer